Dear Fellow Shareholders,
It’s my pleasure to welcome all our shareholders to Immutep’s Annual General Meeting 2023, a year that has seen Immutep report very encouraging clinical data from our lead product candidate, eftilagimod alpha, and transition to become a late-stage biotech.
We are leaders in leveraging LAG-3 immunotherapy to treat cancer, boasting both breadth of clinical development expertise and strong intellectual property in this newly validated area. Beyond efti, we have three other LAG-3 product candidates. We are the only LAG-3 pure play company poised to capture the full potential of LAG-3-based drugs.
For more information, please download the attached PDF.
Download this document
